Zhejiang Hisoar Pharmaceutical Stock Forum

Despite declining revenues, the company's P/S ratio matches the industry, suggesting investors anticipate a business turnaround. However, without medium-term improvements, shareholders may face challenges.

Zhejiang Hisoar Pharmaceutical's net cash position indicates manageable debt, but its revenue shrinkage and EBIT loss over the last year are worrisome. Despite positive free cash flow, lack of revenue growth and positive EBIT are areas of concern.